Astellas Pharma (OTCMKTS:ALPMY) Releases Earnings Results, Beats Expectations By $0.15 EPS

Astellas Pharma (OTCMKTS:ALPMY) released its earnings results on Wednesday. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.15, Zacks reports. Astellas Pharma had a return on equity of 22.21% and a net margin of 6.39%.The business had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.21 billion.

Astellas Pharma Price Performance

Shares of ALPMY stock traded up $0.63 during trading hours on Thursday, reaching $16.00. The company’s stock had a trading volume of 60,272 shares, compared to its average volume of 102,747. Astellas Pharma has a fifty-two week low of $8.37 and a fifty-two week high of $16.00. The firm’s 50 day simple moving average is $13.62 and its 200-day simple moving average is $11.98. The company has a quick ratio of 0.80, a current ratio of 1.03 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $28.95 billion, a price-to-earnings ratio of 34.04 and a beta of 0.18.

Wall Street Analyst Weigh In

Several research firms have weighed in on ALPMY. Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Citigroup cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).